Tue, January 14, 2025
Mon, January 13, 2025

Drugmakers Will Ask Trump to Pause Price Negotiations

Eli Lilly has requested that the Biden administration pause its drug price negotiation program, arguing that the process lacks transparency and could hinder innovation in the pharmaceutical industry. The company expressed concerns that the negotiations, part of the Inflation Reduction Act, might not adequately consider the value of new medicines or the costs associated with their development. Lilly's CEO, David Ricks, emphasized the need for a more open dialogue with the government to ensure that the pricing strategy supports continued research and development while making drugs affordable. This request comes amidst ongoing debates about how best to balance drug affordability with the incentives for pharmaceutical innovation.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/politics/government/lilly-asks-biden-administration-to-pause-drug-price-negotiations/ar-BB1rnZ74 ]